← Human Trials & Peer-Reviewed Studies
A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.
Plain-language guide to PMID 29137465 (2017): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 29137465
- Journal
- Archives of Iranian medicine
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Jamilian M et al. (3 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
The objective of this study was to assess the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk in women with PCOS.
Why It Was Studied
There is scarce data on the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk among women with polycystic ovary syndrome (PCOS).
Who Took Part
The age groups tagged for this paper are young adults and adults, women only.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
Glycemic control and markers of cardio-metabolic risk were assessed at baseline and at the end of trial.
What Was Measured
PubMed files the paper under topics including Biomarkers, Blood Glucose, Calcium, Cholesterol, HDL, Cholesterol, VLDL, Dietary Supplements and Insulin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2017 (Archives of Iranian medicine), a journal based in Iran.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.